NICE approves funding for Ripretinib for patients with GIST in England

NICE has approved NHS funding for ripretinib for adults with advanced gastrointestinal stromal tumours (GIST) in England, marking an important step forward for patients whose cancer has progressed despite multiple previous treatments.

Following a period of consultation with clinicians, patient groups and other stakeholders, the NICE appraisal committee has now completed its review and prepared final draft guidance (FDG). The guidance recommends ripretinib as a treatment option for adults with advanced GIST who have previously received three or more kinase inhibitors, including imatinib. This decision reflects the committee’s assessment of the clinical benefits of ripretinib, alongside updated evidence on its cost effectiveness for use within the NHS.

You can read the final draft guidance by clicking HERE